A failed trial at the American Heart Association leads to pointed fingers at game-changing research on Vascepa, and counter claims of "manufactured controversy."
June 25, 2022
FDA approves tumor-agnostic cancer therapy, Clovis pulls Rubraca indication, Purdue launches opioid reversal, FDA plans advisory committee meeting for Xphozah, and Manarini and AbbVie submit applications.
June 24, 2022
Certain problems such as pain/discomfort, worrying and fear of the persistence/recurrence of atopic dermatitis (AD) became more common among patients with AD since the start of the COVID-19 pandemic.
June 23, 2022
Respondents can win a $250 gift card.
June 23, 2022
Demand for birth control obtained through telehealth or without a prescription continues to grow, and some states have loosened up their rules. Meanwhile, groups and organizations involved in contraception are bracing themselves for the effects of the U.S. Supreme Court decision today overturned Roe v. Wade and the constitutional right to abortion.
June 18, 2022
In COVID-19 news, the FDA expanded emergency use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 Vaccine for children down to 6 months of age. The FDA also approved Skyrizi for Crohn’s disease, Olumiant for alopecia, as well as two rare disease therapies: Imcivree for obesity associated BBS and Amvuttra for neuropathy associated with rare disease. Additionally, FDA extended the PDUFA date Brukinsa.
June 16, 2022
Technical and regulatory hurdles abound, but another challenge is finding enough providers who are comfortable and competent with artificial intelligence technology.
June 16, 2022
The company also announced yesterday that will revive Wellpoint name in some markets.
June 15, 2022
Amgen’s biologic won’t have biosimilar competition till 2029. But the possibility that up to 11 Humira biosimilars may come on the market in 2023 could exert some downward pressure on Enbrel’s price.
June 15, 2022
A review of multiple studies found the COVID-19 exacerbated the economic, social and psychological difficulties that patients with cancer were already facing because of their cancer.
June 12, 2022
Adding tax-preferred savings, perhaps with an employer match, can prompt employees to accumulate assets so they are prepared to shoulder out-of-pocket costs. Using reference-based pricing can establish benchmark fees and put a ceiling on payments across a network.